EcoDrugPlus

Somatostatin Receptor Type 1-Like

Ensembl ID : ENSSFOG00015020885
Gene Symbol: LOC108934222
2 Cross references
206 Possible Orthologues:

Somatostatin Receptor Type 1-Like

Ensembl ID : ENSSFOG00015013788
Gene Symbol: LOC108923740
2 Cross references
158 Possible Orthologues:

Somatostatin Receptor Type 5-Like

Ensembl ID : ENSSFOG00015010168
Gene Symbol: LOC108925941
2 Cross references
188 Possible Orthologues:

Sphingosine Kinase 2

Ensembl ID : ENSSFOG00015000102
Gene Symbol: SPHK2
3 Cross references
202 Possible Orthologues:

Sphingosine-1-Phosphate Receptor 1

Ensembl ID : ENSSFOG00015017950
Gene Symbol: S1PR1
1 Cross references
199 Possible Orthologues:

Sphingosine-1-Phosphate Receptor 1

Ensembl ID : ENSSFOG00015017824
Gene Symbol: S1PR1
3 Cross references
199 Possible Orthologues:

Spleen Associated Tyrosine Kinase

Ensembl ID : ENSSFOG00015007492
Gene Symbol: SYK
3 Cross references
200 Possible Orthologues:

Steroid 17-Alpha-Hydroxylase/17,20 Lyase

Ensembl ID : ENSSFOG00015003625
Gene Symbol: LOC108933747
3 Cross references
210 Possible Orthologues:

Steroid 5 Alpha-Reductase 2

Ensembl ID : ENSSFOG00015000636
Gene Symbol: SRD5A2
3 Cross references
260 Possible Orthologues:

Steroid-5-Alpha-Reductase, Alpha Polypeptide 2b

Ensembl ID : ENSSFOG00015009575
Gene Symbol: SRD5A2B
1 Cross references
261 Possible Orthologues:

Sterol O-Acyltransferase 1

Ensembl ID : ENSSFOG00015016406
Gene Symbol: SOAT1
3 Cross references
210 Possible Orthologues:

Tachykinin Receptor 1

Ensembl ID : ENSSFOG00015018625
Gene Symbol: TACR1
3 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).